On April 21, 2026, Maze Therapeutics, Inc. announced an underwriting agreement to issue 5,540,000 shares and 850,000 pre-funded warrants at $23.50 and $23.499 each, respectively, estimating net proceeds of about $144.7 million to fund R&D and general corporate purposes.